ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease Trial): An Estimated 36 Subjects to Undergo a Total Eval Period of 15 Months

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

January 14, 2021

ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease) trial (first patient enrolled) evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson’s Disease (PD) was announced by Medtronic.

Adaptive deep brain stimulation is an investigational feature of the Percept™ PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson’s disease based on a patient’s clinical state.

The randomized study will take place across 12 study sites at leading Movement Disorders research centers in the United States, Europe, and Canada. An estimated 36 subjects will undergo a total evaluation period of 15 months.

The primary endpoint of ADAPT-PD will compare standard continuous DBS (cDBS) to aDBS for hours of ‘On’ time without troublesome dyskinesias, a measure of treatment efficacy versus side effects, as reported by patient diary. Qualifying subjects in the study will receive cDBS at baseline followed by randomized evaluation of two different aDBS algorithms in a blinded manner.

Dr. Helen Bronte-Stewart, the John E. Cahill Family Professor in the Department of Neurology and Neurological Sciences at Stanford University and who is the North American principal investigator for the ADAPT-PD study, enrolled the first patient at the Stanford Movement Disorders Center.

Dr. Bronte-Stewart and her collaborators previously laid the foundation for ADAPT-PD by performing the first closed loop deep brain stimulation studies in Parkinson’s disease using an investigational prototype research-only system (Activa™ PC+S-Nexus D3). ADAPT-PD represents an evolutionary leap from these early studies in that sensing of brain signals and automated adjustment of stimulation are performed by using unlocked investigational features of the commercially available Percept PC DBS device, allowing patients in the study to be both treated and measured while outside the clinic.

According to the Parkinson’s Foundation, more than 10 million people worldwide are living with Parkinson’s disease and while similar, the progression of symptoms is often different from one patient to another due to the diversity of the disease. People with PD may experience tremor; slowness of movements (bradykinesia); limb rigidity; gait and balance challenges.

DBS is a well-established, safe and effective therapy for the treatment of motor symptoms in PD, including tremor (shaking); slowed movement (bradykinesia); and stiffness (rigidity) when medications aren’t as effective as they used to be. Opportunities exist to improve the efficacy of DBS therapy. Current commercially-approved DBS systems deliver stimulation continuously (cDBS) and are adjusted manually within physician-defined limits to optimize therapy for the patient.

In contrast, aDBS therapy may individualize and optimize PD therapy for the same motor symptoms as with cDBS by automatically adjusting stimulation within physician-defined limits, based on brain signals detected by the DBS system. ADAPT-PD will be using the Percept PC DBS system with investigational aDBS feature. While the aDBS feature is investigational and has not been approved for commercial use, the Percept PC device (cDBS) was approved by the FDA in June 2020.

The Percept PC device (cDBS) utilizes proprietary BrainSense™ technology making it the only DBS system with the ability to capture patient-specific brain signals. The sensing feature of the Percept PC system is intended for use in patients receiving DBS where chronically-recorded bioelectric data may provide useful, objective information regarding patient clinical status. Clinical benefits of brain-sensing have not been established.

“Percept PC was developed with a significant amount of capabilities built into its system. We see this technology evolving to deliver even more value over time. The recently initiated ADAPT-PD is the first trial to gather clinical evidence to unlock those capabilities,” said Mike Daly, vice president and general manager of the Brain Modulation business, which is reported as part of the Restorative Therapies Group at Medtronic. “Additionally, stimulation adjusted based on patient need, aDBS, could reduce total power output and possibly extend the life of the device.”

Medtronic is a pioneer in DBS, developing a small, pacemaker-like device, placed under the skin of the chest or abdomen, to send electronic signals to an area in the brain that controls movement. DBS may help control movement symptoms associated with PD when medications are no longer as effective as they used to be. To date, more than 175,000 patients have been implanted with Medtronic DBS devices for management of Parkinson’s symptoms and other conditions such as Essential Tremor, Epilepsy, Dystonia and OCD.

“aDBS technology will allow DBS to be responsive in real-time, communicating with the patient’s brain, as needed – which could reduce the amount of programming burden on a clinician,” added Professor Andrea Kühn, head of Movement Disorders and Neuromodulation, Charité University Hospital, Berlin. Professor Kühn is one of the leading scientists on electrophysiological markers for PD and designers of the ADAPT study; her team at the Charité, Universitätsmedizin Berlin implanted the first Percept PC DBS patient in the world.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.